Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Completed · Phase 3 · Has a placebo group
Conditions studied: Psoriatic Arthritis
In brief
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFα therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.
Key facts
- Study ID
- NCT01752634
- Run by
- Novartis Pharmaceuticals
- People needed
- 397
- Starts
- 2013-04-14
- Expected to finish
- 2019-01-09
- Last updated by the study team
- 2020-05-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Aventura, Florida, United States
- Novartis Investigative Site — Palm Harbor, Florida, United States
- Novartis Investigative Site — Sarasota, Florida, United States
- Novartis Investigative Site — Tamarac, Florida, United States
- Novartis Investigative Site — Tampa, Florida, United States
- Novartis Investigative Site — Zephyrhills, Florida, United States
- Novartis Investigative Site — Lincoln, Nebraska, United States
- Novartis Investigative Site — Omaha, Nebraska, United States
- Novartis Investigative Site — Freehold, New Jersey, United States
- Novartis Investigative Site — Syracuse, New York, United States
- Novartis Investigative Site — Asheville, North Carolina, United States
- Novartis Investigative Site — Charlotte, North Carolina, United States
- Novartis Investigative Site — Oklahoma City, Oklahoma, United States
- Novartis Investigative Site — Oklahoma City, Oklahoma, United States
- Novartis Investigative Site — Duncansville, Pennsylvania, United States
- Novartis Investigative Site — Charleston, South Carolina, United States
- Novartis Investigative Site — Columbia, South Carolina, United States
- Novartis Investigative Site — Greenville, South Carolina, United States
- Novartis Investigative Site — League City, Texas, United States
- Novartis Investigative Site — Mesquite, Texas, United States
- Novartis Investigative Site — Kogarah, New South Wales, Australia
- Novartis Investigative Site — Maroochydore, Queensland, Australia
- Novartis Investigative Site — Hobart, Tasmania, Australia
- Novartis Investigative Site — Malvern East, Victoria, Australia
- Novartis Investigative Site — Peoria, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.